Compare FMC Corp (FMC) vs Hinge Health Inc. Class A Common Stock (HNGE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FMC Corp vs Hinge Health Inc. Class A Common Stock — how do they compare? FMC Corp trades at $8.05 (market cap $1.29B), while Hinge Health Inc. Class A Common Stock trades at $103.96 (market cap $8.48B). The key difference: Hinge Health Inc. Class A Common Stock is far larger — about 6.6× FMC Corp's market cap, and FMC Corp pays a 3.85% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold FMC Corp for 68 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| FMC | HNGE | |
|---|---|---|
Market Cap | $1.29B | $8.48B |
Volume | 3,528,603 | 879,799 |
Sector | Basic Materials | Health |
52-Week High | $30.63 | $105.14 |
52-Week Low | $8.09 | $31.17 |
Typical Hold Time | 68 Days | 0 Days |
Enterprise Value | $5.10B | $8.10B |
Dividend Yield | 3.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FMC trades at $8.09, down 2.76% on the day, with a bearish technical signal and weak fundamentals including a net income margin of -84.83% and negative ROE of -91.47% for 2025. Recent earnings show mixed results with Q2 2026 beating estimates, but revenue has declined from $5.8B in 2022 to $3.47B in 2025. Positive developments include a regulatory filing for rimisoxafen in Brazil and a minority equity investment by Tessenderlo Group, yet cash flow from operations remains negative.
The outlook is cautious; while analyst consensus is a buy with a $14.20 price target, high debt and cyclical industry headwinds pose significant risks. Aggressive deleveraging efforts may improve financial stability, but persistent revenue declines and negative profitability underscore substantial challenges for near-term recovery.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →
